Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have shown promising benefits in the management of cardiovascular and renal outcomes in patients with type 2 diabetes mellitus (T2DM) and CKD [2]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.